雷尼替丁对消化性溃疡的愈合及复发预防作用

Ulcer healing and relapse prevention by ranitidine in peptic ulcer disease.

作者信息

Liedberg G, Davies H J, Enskog L, Eriksson S, Frederiksen B, Graffner H, Hradsky M, Oscarson J, Rydberg B, Simert G

出版信息

Scand J Gastroenterol. 1985 Oct;20(8):941-4. doi: 10.3109/00365528509088852.

Abstract

Ranitidine, 300 mg daily, was given to 92 patients with duodenal ulcer (DU), 38 with prepyloric ulcer (PPU), and 21 with gastric corporeal ulcer (GCU). The healing rates at 4 weeks differed for the different types of ulcers (P less than 0.01), being 91% for DU, 68% for PPU, and 81% for GCU. After established ulcer healing, maintenance treatment with either ranitidine, 100 mg twice daily or 150 mg at night, or placebo was given for 1 year or until ulcer relapse in a total of 108 patients--71 with DU, 24 with PPU, and 13 with GCU. There were no significant differences in relapse rates between the two groups treated with active drug or between the three ulcer groups. However, the overall relapse rate in the active drug groups was 16%, against 72% in the placebo group (P less than 0.001).

摘要

给92例十二指肠溃疡（DU）患者、38例幽门前溃疡（PPU）患者和21例胃体部溃疡（GCU）患者每日服用300毫克雷尼替丁。不同类型溃疡在4周时的愈合率有所不同（P<0.01），DU的愈合率为91%，PPU为68%，GCU为81%。在溃疡愈合确立后，对总共108例患者——71例DU患者、24例PPU患者和13例GCU患者，采用雷尼替丁每日两次每次100毫克或每晚150毫克进行维持治疗，或给予安慰剂，治疗1年或直至溃疡复发。接受活性药物治疗的两组之间或三个溃疡组之间的复发率无显著差异。然而，活性药物组的总体复发率为16%，而安慰剂组为72%（P<0.001）。